TY - JOUR AU - Demuth, Christina AU - Madsen, Anne Tranberg AU - Weber, Britta AU - Wu, Lin AU - Meldgaard, Peter AU - Sorensen, Boe Sandahl PY - 2018 DA - 2018/02/15 TI - The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment JO - BMC Cancer SP - 191 VL - 18 IS - 1 AB - Lung cancer patients with an activating mutation in the EGFR (epidermal growth factor receptor) can develop resistance to erlotinib treatment, which is often mediated by the T790M resistance mutation in EGFR. The difficulties in obtaining biopsies at progression make it challenging to investigate the appearance of the T790M mutation at progression in large patient cohorts. We have used cell free DNA (cfDNA) from patients treated with erlotinib to investigate if the development of a T790M mutation coincides with the presence of an activating EGFR mutation in the pre-treatment blood sample. SN - 1471-2407 UR - https://doi.org/10.1186/s12885-018-4108-0 DO - 10.1186/s12885-018-4108-0 ID - Demuth2018 ER -